The compound RVX-208 was an early BD2-specific compound; however, it exhibited only moderate BD2 potency (>100 nM, IC50 [the concentration that inhibits response by 50%] = 2 µM in our BRDT-BD2 AlphaScreen assay) and selectivity over BD1 domains (∼10-fold) (21)

Didn't we already know that RVX-208 didn't have a significant impact on BRDT?   The 'T' refers to the testes.  I didn't read through the artilce so I am not sure why this study is referencing impacts on BRDT.  I was under the impression that RVX-208's lack of impact on BRDT was a good thing, not a bad thing.

Any comments on this from the scientist?